A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
for Hidradenitis Suppurativa
Drug: Upadacitinib
87 locations incl. Birmingham
Sponsor: AbbVie
Sex: All·Age: 12+
Code: NCT05889182·Phase 3·Recruiting